Company Filing History:
2 out of 12,160 
2 out of 378 
Years Active: 2021-2023
Title: A Spotlight on Inventor Jan Dreher: Innovations in Medicine
Introduction: Jan Dreher, a notable inventor based in Wuppertal, Germany, has made significant contributions to the field of medicine. With a focus on innovative compounds targeting serious health conditions, his work exemplifies the intersection of scientific research and practical applications in healthcare.
Latest Patents: Dreher holds two patents that showcase his expertise in developing therapeutics aimed at treating cardiovascular and renal disorders. His latest patent, titled "MASP inhibitory compounds and uses thereof," involves novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds. These compounds are designed for treatment and prevention of various diseases, specifically targeting renal and cardiovascular disorders, as well as ischemia reperfusion injuries.
The second patent, "Substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof," describes substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds, their preparation methods, and their use in pharmaceutical compositions. This invention aims to address cardiovascular and renal diseases, either as standalone treatments or in combination with other active ingredients.
Career Highlights: Throughout his career, Jan Dreher has worked with prominent companies, including Bayer Aktiengesellschaft and Bayer Pharma Aktiengesellschaft. His experience in these organizations has undoubtedly contributed to his development of innovative solutions in the medical field.
Collaborations: Dreher has collaborated with notable coworkers, including Anja Giese and Jürgen Klar. These partnerships have played an important role in advancing his research and bringing his inventions to fruition.
Conclusion: Jan Dreher continues to be a driving force in medical innovation with his patents focused on critical health issues. His work not only demonstrates his ingenuity as an inventor but also holds the potential to significantly impact patient care through advancements in therapeutic treatments.